Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8
August 28, 2017
- MHLW Health Policy Bureau to Initiate a New Project to Increase Understanding of Biosimilars; FY2018 Budget Request
August 28, 2017
- MHLW Pharmaceutical Safety Bureau Seeks 10.3 Billion Yen in FY2018 Budget; Includes Funding for 6 Add’l Personnel at PMDA
August 28, 2017
- MHLW Working Group to Kick Off Discussions on Guidelines to Address Elderly Polypharmacy
August 25, 2017
- MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
- MHLW Council Recommends Public Knowledge-Based Applications for 2 Products Including Velcade
August 25, 2017
- MHLW Presents Steps Responding to Chuikyo Reps’ Concerns for “Willing-to-Pay Cost” Survey
August 24, 2017
- Chuikyo OKs MHLW’s Discussion Timeline on CEA, 3 Subcommittees to Hold Joint Debates
August 24, 2017
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
- Leftover Spinraza in 9-Million-Yen Vial Must Be Discarded, Can’t Be Saved for Next Time: MHLW Official
August 23, 2017
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
- Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
- MHLW Advisory Panel to Review Budesonide Rectal Foam on Sept. 1
August 21, 2017
- 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
- NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
- “Pediatric Treatment” Excluded from Appraisal Adjustment Factors in Pilot Program: Chuikyo
August 10, 2017
- MHLW Wants to Use Past Surveys, Overseas Examples for ICER Yardstick in CEA Pilot Program, Plan Draws Fire from Payers Reps: Chuikyo
August 10, 2017
- Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…